Literature DB >> 15662039

Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage.

Andrew M Naidech1, Kurt T Kreiter, Nazli Janjua, Noeleen Ostapkovich, Augusto Parra, Christopher Commichau, E Sander Connolly, Stephan A Mayer, Brian-Fred M Fitzsimmons.   

Abstract

BACKGROUND AND
PURPOSE: Phenytoin (PHT) is routinely used for seizure prophylaxis after subarachnoid hemorrhage (SAH), but may adversely affect neurologic and cognitive recovery.
METHODS: We studied 527 SAH patients and calculated a "PHT burden" for each by multiplying the average serum level of PHT by the time in days between the first and last measurements, up to a maximum of 14 days from ictus. Functional outcome at 14 days and 3 months was measured with the modified Rankin scale, with poor functional outcome defined as dependence or worse (modified Rankin Scale > or =4). We assessed cognitive outcomes at 14 days and 3 months with the telephone interview for cognitive status.
RESULTS: PHT burden was associated with poor functional outcome at 14 days (OR, 1.5 per quartile; 95% CI, 1.3 to 1.8; P<0.001), although not at 3 months (P=0.09); the effect remained (OR, 1.6 per quartile; 95% CI, 1.2 to 2.1; P<0.001) after correction for admission Glasgow Coma Scale, fever, stroke, age, National Institutes of Health Stroke Scale > or =10, hydrocephalus, clinical vasospasm, and aneurysm rebleeding. Seizure in hospital (OR, 4.1; 95% CI, 1.5 to 11.1; P=0.002) was associated with functional disability in a univariate model only. Higher quartiles of PHT burden were associated with worse telephone interview for cognitive status scores at hospital discharge (P<0.001) and at 3 months (P=0.003).
CONCLUSIONS: Among patients treated with PHT, burden of exposure to PHT predicts poor neurologic and cognitive outcome after SAH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15662039     DOI: 10.1161/01.STR.0000141936.36596.1e

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  72 in total

Review 1.  Intracranial hemorrhage.

Authors:  Andrew M Naidech
Journal:  Am J Respir Crit Care Med       Date:  2011-11-01       Impact factor: 21.405

Review 2.  The utility of EEG, SSEP, and other neurophysiologic tools to guide neurocritical care.

Authors:  Eric S Rosenthal
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

3.  Intensive care unit management of aneurysmal subarachnoid hemorrhage.

Authors:  Jennifer E Fugate; Alejandro A Rabinstein
Journal:  Curr Neurol Neurosci Rep       Date:  2012-02       Impact factor: 5.081

4.  Levetiracetam is associated with improved cognitive outcome for patients with intracranial hemorrhage.

Authors:  Scott Taylor; Robin J Heinrichs; Jeff M Janzen; As'ad Ehtisham
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

Review 5.  Seizures and anticonvulsants after aneurysmal subarachnoid hemorrhage.

Authors:  Giuseppe Lanzino; Pietro Ivo D'Urso; Jose Suarez
Journal:  Neurocrit Care       Date:  2011-09       Impact factor: 3.210

Review 6.  Controversies in the care of children with acute brain injury.

Authors:  Steven Weinstein
Journal:  Curr Neurol Neurosci Rep       Date:  2006-03       Impact factor: 5.081

Review 7.  The AHA Guidelines for the Management of SAH: what we know and so much we need to learn.

Authors:  Alejandro A Rabinstein
Journal:  Neurocrit Care       Date:  2009-04-24       Impact factor: 3.210

8.  The utility of conductive plastic electrodes in prolonged ICU EEG monitoring.

Authors:  Rohit R Das; Brendan P Lucey; Sherry H-Y Chou; Patricio S Espinosa; Amir A Zamani; Barbara A Dworetzky; Edward B Bromfield; Jong Woo Lee
Journal:  Neurocrit Care       Date:  2008-09-20       Impact factor: 3.210

Review 9.  Drug treatment of acute ischemic stroke.

Authors:  Sameer Bansal; Kiranpal S Sangha; Pooja Khatri
Journal:  Am J Cardiovasc Drugs       Date:  2013-02       Impact factor: 3.571

Review 10.  Critical care management of subarachnoid hemorrhage.

Authors:  Joshua M Levine
Journal:  Curr Neurol Neurosci Rep       Date:  2008-11       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.